1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017

  • February 2017
  • 129 pages
  • Currentpartnering
Report ID: 3679171

Summary

Table of Contents

Search Inside

Summary
The Global Pharmacogenomics Partnering Terms & Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the pharmacogenomics partnering deals and agreements entered into by the worlds leading healthcare companies.



Description
The Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Pharmacogenomics agreements announced in the healthcare sectors.
Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by correlating gene expression or single nucleotide polymorphisms with a drug’s efficacy or toxicity.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 300 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of Pharmacogenomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Pharmacogenomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Pharmacogenomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active Pharmacogenomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Pharmacogenomics dealmaking with a brief summary followed by a comprehensive listing of Pharmacogenomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Pharmacogenomics partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Pharmacogenomics partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Pharmacogenomics partnering company A-Z, deal type definitions and Pharmacogenomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Pharmacogenomics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pharmacogenomics technologies and products.

Key benefits
- Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 provides the reader with the following key benefits:
- In-depth understanding of pharmacogenomics deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of pharmacogenomics agreements with real life case studies
- Detailed access to actual pharmacogenomic contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a pharmacogenomic agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to pharmacogenomic trends and structure of deals entered into by leading companies worldwide.
Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 includes:
- Trends in pharmacogenomics dealmaking in the biopharma industry since 2010
- Analysis of pharmacogenomic deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life pharmacogenomics deals
- Access to over 300 pharmacogenomics online deal records
- The leading pharmacogenomics deals by value since 2010
- Most active pharmacogenomics dealmakers since 2010
- The leading pharmacogenomics partnering resources

In Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive access to available deals and contract documents for over 300 pharmacogenomic deals.

Analyzing actual contract agreements allows assessment of the following:
- What are the precise pharmacogenomic rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cancer Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • $ 5795
  • Industry report
  • May 2017
  • by Transparency Market Research

Global Cancer Biomarkers Market: Overview Biomarkers are the substance or molecules found in blood, other body fluids or tissues which states the normal and abnormal condition of the body, biomarkers ...

Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to 202

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...

Biomarkers Enabling Diabetes and Obesity Management

  • $ 4950
  • Industry report
  • March 2017
  • by Frost & Sullivan

Novel Biomarker Research is Likely to Transform the Future of Obesity and Diabetes Management Obesity and diabetes are areas of growing concern across both, developed and developing countries. The rising ...


Download Unlimited Documents from Trusted Public Sources

Genomics Industry in the US

  • June 2017
    63 pages
  • Genomics  

  • United States  

    North America  

View report >

Health Care Provider Industry in the US - Forecast

  • May 2017
    9 pages
  • Health Care Pro...  

    Lung Cancer  

    Cancer  

  • United States  

    North America  

View report >

Genomics Industry in Denmark

  • May 2017
    7 pages
  • Genomics  

  • Denmark  

View report >

Related Market Segments :

Biomarker
Genomics
Laboratory
Hospital
R&D

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.